Skip to main content
Journal cover image

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.

Publication ,  Journal Article
Kibel, AS; Inman, BA; Pachynski, RK; Vu, T; Sheikh, NA; Petrylak, DP
Published in: Journal of the National Cancer Institute
February 2022

Sipuleucel-T, an autologous cellular immunotherapy, was approved to treat metastatic castration-resistant prostate cancer in 2010 in the United States. Treatment with sipuleucel-T primes the immune system to target prostate acid phosphatase, which is expressed by prostate cancer cells, potentially leading to lysis of cancer cells. Expanding on previously reported indirect evidence of cell killing with sipuleucel-T treatment, we sought to provide direct evidence of cell lysis through visualization. We used advanced video technology and available samples of peripheral blood mononuclear cells from subjects enrolled in the STAMP trial (NCT01487863). Isolated CD8+ T cells were used as effector cells and cocultured with autologous monocytes pulsed with control or target antigens. Differentially stained effector and target cells were then video recorded during coculture. Here, we present video recordings and analyses of T cells from sipuleucel-T-treated subjects showing-for the first time-direct lysis of cells that express prostate cancer target antigens, prostate acid phosphatase, or prostate-specific antigen.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of the National Cancer Institute

DOI

EISSN

1460-2105

ISSN

0027-8874

Publication Date

February 2022

Volume

114

Issue

2

Start / End Page

310 / 313

Related Subject Headings

  • United States
  • Tissue Extracts
  • Prostatic Neoplasms
  • Prostate
  • Oncology & Carcinogenesis
  • Male
  • Leukocytes, Mononuclear
  • Immunotherapy
  • Humans
  • Cancer Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kibel, A. S., Inman, B. A., Pachynski, R. K., Vu, T., Sheikh, N. A., & Petrylak, D. P. (2022). Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. Journal of the National Cancer Institute, 114(2), 310–313. https://doi.org/10.1093/jnci/djab025
Kibel, Adam S., Brant A. Inman, Russell K. Pachynski, Tuyen Vu, Nadeem A. Sheikh, and Daniel P. Petrylak. “Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.Journal of the National Cancer Institute 114, no. 2 (February 2022): 310–13. https://doi.org/10.1093/jnci/djab025.
Kibel AS, Inman BA, Pachynski RK, Vu T, Sheikh NA, Petrylak DP. Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. Journal of the National Cancer Institute. 2022 Feb;114(2):310–3.
Kibel, Adam S., et al. “Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.Journal of the National Cancer Institute, vol. 114, no. 2, Feb. 2022, pp. 310–13. Epmc, doi:10.1093/jnci/djab025.
Kibel AS, Inman BA, Pachynski RK, Vu T, Sheikh NA, Petrylak DP. Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens. Journal of the National Cancer Institute. 2022 Feb;114(2):310–313.
Journal cover image

Published In

Journal of the National Cancer Institute

DOI

EISSN

1460-2105

ISSN

0027-8874

Publication Date

February 2022

Volume

114

Issue

2

Start / End Page

310 / 313

Related Subject Headings

  • United States
  • Tissue Extracts
  • Prostatic Neoplasms
  • Prostate
  • Oncology & Carcinogenesis
  • Male
  • Leukocytes, Mononuclear
  • Immunotherapy
  • Humans
  • Cancer Vaccines